Human Anti-CD79A Recombinant Antibody (clone JCB117) (CAT#: FAMAB-1082CQ)

Figure 1 Reactivity of antibody JCB117 by immunoprecipitation from lysates of sudace iodinated human B cells (Ramos cell line).

(A) The antibody fails to immunoprecipitate CD79a (mb-l) from an NP-40 lysate, whereas the control antibody HM57 gives the expected reaction. Normal mouse serum (NMS) provides a negative control. (B) After treatment of the NP-40 lysate with SDS some weak reactivity of JCB117 with CD79a (mb-1) is observed. (C) The lysates shown in (B) were reduced and alkylated, and some residual CD79 mb-1) could then be immunoprecipitated by JCB117.

Mason, D. Y., Cordell, J. L., Brown, M. H., Borst, J., Jones, M., Pulford, K., ... & Stein, H. (1995). CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples.

Figure 2 Reactivity of antibody JCB117 with paraffin embedded tumor biopsies.

(A and B) Antibody JCB117 detects the CD79a polypeptide in neoplastic B cells in lymph node (large cell lymphoma), spleen (hairy cell leukemid, brain (large cell lymphoma), gastrointestinal tract (MALT lymphoma), and marrow trephine (chronic lymphocytic leukemia). The inset illustration for the central nervous system lymphoma shows adjacent normal brain. Normal megakaryocytes are arrowed in the chronic lymphocytic leukemia sample. A case of acute myeloid leukaemia (AML) is unstained, except for normal B cells. (C) Antibody JCB117 also detects the CD79a polypeptide in immature B cells as illustrated by three examples of precursor cell acute lymphoblastic leukemia in testis, salivary gland, and marrow trephine. All sections stained by the APAAP immunoalkaline phosphatase procedure with the exception of the brain biopsy (indirect immunoperoxidase technique).

Mason, D. Y., Cordell, J. L., Brown, M. H., Borst, J., Jones, M., Pulford, K., ... & Stein, H. (1995). CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples.

Figure 3 Immunocytochemical reactivity.

(A) Antibody JCB117 detects CD79a in normal plasma cells, as Seen in this marrow trephine section. APAAP technique. (B) R also labels some plasma cell neoplasms (Table 11, as illustrated by this cutaneous plasmacytoma (expressing monoclonal kappa light chains), which is positive for CD79a (antibody JCB1171, but CD20-negative, in keeping with the loss of CD20 by normal plasma cells. ABC immunoperoxidase technique. (C) A gastrointestinal Bell lymphoma (MALT lymphoma) is shown in which two cellular compartments could be identified. In the deep mucosa neoplastic centrocytelike cells typical of this neoplasm are seen (shown at high magnification in the lower inset illustrations). They are positive for both CD20 and CD79a (antibody JCB117). In contrast, the upper mucosa is densely infiltrated with monoclonal plasma cells (upper inset illustrations), representing terminally differentiated neoplastic B cells, which are positive for CD79a (antibody JCB117) but CD20-negative. ABC immunoperoxidase technique.

Mason, D. Y., Cordell, J. L., Brown, M. H., Borst, J., Jones, M., Pulford, K., ... & Stein, H. (1995). CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples.